TABLE 3.

Published clinical trials of remimazolam in procedural sedation. NA = not available/applicable, GI = gastrointestinal. N = number of patients.

Trial ID	Procedure	Phase	ASA class	N	Primary endpoint	Salt form	Dose	Co-treatment	Comparator	Ref
NCT00869440	Upper GI endoscopy	II	I - II	100	Success of procedure	Besylate	0.1–0.2 mg/kg	NA	Midazolam	Borkett et al. (2015)
NCT01145222	Colonoscopy	II	I - III	162	Success of procedure	Besylate	5–8 mg plus 2–3 mg top-ups	Fentanyl	Midazolam	Pambianco et al. (2016)
NCT02290873	Colonoscopy	III	I - III	461	Success of procedure	Besylate	5 mg plus 2.5 mg top-ups	Fentanyl	Midazolam, placebo	Rex et al. (2018)
NCT02296892	Bronchoscopy	III	I - III	446	Success of procedure	Besylate	5 mg plus 2.5 mg top-ups	Fentanyl	Midazolam, placebo	Pastis et al. (2019)
NCT02532647	Colonoscopy	III	III-IV	79	Success of procedure	Besylate	2.5–5.0 mg plus 1.25–2.5 mg top-ups	Fentanyl	Midazolam, placebo	Rex et al. (2021)
NCT03779061	Colonoscopy	III	I - II	384	Successful sedation	Tosylate	5 mg plus 2.5 mg top-ups	Fentanyl	Propofol	Chen et al., (2020a)
NCT03425474	Upper GI endoscopy	III	I - II	384	Successful sedation	Tosylate	5 mg plus 2.5 mg top-ups	Fentanyl	Propofol	Chen et al. (2021)
ChiCTR-2000038252	Hysteroscopy	II	I-II	82	Adverse events	Besylate	0.2 mg/kg/min then 1 mg/kg/h	Remifentanil	Propofol	Zhang et al. (2021)